Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Sara LodiCASCADE Collaboration in EuroCoord


Recent updates of human immunodeficiency virus (HIV) treatment guidelines have raised the CD4+ cell count thresholds for antiretroviral therapy initiation from 350 to 500 cells/mm(3) in the United States and from 200 to 350 cells/mm³ in mid- and low-income countries. Robust data of time from HIV seroconversion to CD4+ cell counts of 200, 350, and 500 cells/mm³ are lacking but are needed to inform health care planners of the likely impact and cost effectiveness of these and possible future changes in CD4+ cell count initiation threshold. Using Concerted Action on Seroconversion to AIDS and Death in Europe data from individuals with well-estimated dates of HIV seroconversion, we fitted mixed models on the square root of CD4+ cell counts measured before combined antiretroviral therapy (cART) initiation. Restricting analyses to adults (age >16 years), we predicted time between seroconversion and CD4+ cell count <200, <350, and <500 cells/mm³ as well as CD4+ cell count distribution and proportions reaching these thresholds at 1, 2, and 5 years after seroconversion. Median (interquartile range [IQR]) follow-up for the 18495 eligible individuals from seroconversion while cART-free was 3.7 years (1.5, 7). Most of the subjects were male...Continue Reading


Dec 22, 1999·AIDS·M PrinsA van den Hoek
Dec 22, 1999·International Journal of Epidemiology·P RoystonW Sauerbrei
Sep 23, 2003·Journal of Acquired Immune Deficiency Syndromes : JAIDS·UNKNOWN CASCADE Collaboration
Jan 19, 2007·The Journal of Infectious Diseases·Maria DorrucciUNKNOWN Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration
May 16, 2007·Infectious Disease Clinics of North America·Nicola M Zetola, Christopher D Pilcher
Oct 11, 2008·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Vanni BorghiRoberto Esposito
Apr 3, 2009·The New England Journal of Medicine·Mari M KitahataUNKNOWN NA-ACCORD Investigators
May 9, 2009·AIDS·Pénélope TroudeUNKNOWN ANRS Primo cohort
Mar 11, 2010·AIDS·Nigel O'Farrell
Jul 20, 2010·JAMA : the Journal of the American Medical Association·Melanie A ThompsonUNKNOWN International AIDS Society-USA

❮ Previous
Next ❯


Mar 15, 2012·Current HIV/AIDS Reports·Meagan O'Brien, Martin Markowitz
Jan 18, 2013·The New England Journal of Medicine·Tuan LeSunil K Ahuja
Oct 12, 2013·BMC Infectious Diseases·Paola ScognamiglioUNKNOWN SENDIH Study Group
Jul 18, 2012·PLoS Medicine·UNKNOWN HIV Modelling Consortium Treatment as Prevention Editorial Writing Group
Nov 19, 2013·PloS One·Sara LodiUNKNOWN CASCADE Collaboration in EuroCoord
Dec 7, 2013·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·V CambianoM J van de Laar
Jan 25, 2014·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·A AghaizuV Delpech
Dec 4, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Fredrick Sawe, Shahin Lockman
Oct 22, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ruthie B BirgerSally L Hodder
Mar 25, 2014·Current HIV/AIDS Reports·Fumiyo NakagawaJens D Lundgren
Jun 14, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kim C E SigaloffJulio Montaner
Nov 12, 2014·Current HIV/AIDS Reports·Mark HullJulio S G Montaner
Apr 3, 2016·Clinical Medicine : Journal of the Royal College of Physicians of London·Sarah Fidler, Julie Fox
Oct 20, 2015·Bulletin of the World Health Organization·Jacques DA NdawinzVirginie Supervie
Nov 12, 2014·Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine·Roger C McIntoshNeil Schneiderman
Nov 3, 2016·Infectious Diseases·Jaran EriksenAnders Sönnerborg
Jan 5, 2017·AIDS Patient Care and STDs·Matthew R GoldenJulia C Dombrowski
Sep 21, 2016·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Chaitra GopalappaStephanie L Sansom
Mar 17, 2017·AIDS·Tara D Mangal, UNKNOWN UNAIDS Working Group on CD4 Progression and Mortality Amongst HIV Seroconverters including the CASCADE Collaboration in Euro
Jan 29, 2014·AIDS·Sharmistha MishraUNKNOWN Strategic Epi-ART in India Modelling Team
Dec 31, 2015·Journal of the International Association of Providers of AIDS Care·Reuben GranichJosé M Zuniga
Apr 27, 2012·Statistical Methods in Medical Research·Ronald B Geskus
Jan 9, 2014·International Journal of STD & AIDS·I ReevesT Whitehead
Nov 15, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Hendramoorthy MaheswaranStavros Petrou
Feb 20, 2016·Journal of the International AIDS Society·David MamanJean-François Etard
Dec 11, 2014·Journal of the International AIDS Society·Brooke E NicholsDavid A M C van de Vijver
Dec 1, 2017·Journal of the International Association of Providers of AIDS Care·Kelly A HennesseyJean W Pape
Oct 31, 2017·PloS One·Nikoloz ChkhartishviliTengiz Tsertsvadze

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.